Clinical trial TG6002.02
A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2a |
Academic trial | Non |
Sponsor | Transgene S.A. |
EudraCT Identifier | 2018-000039-28 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03724071 |
Inclusion criteria | After standard therapy / RECIST 1.1 |
Last update |